Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has announced the results of a study demonstrating the effectiveness of a pTau217 screening assay in reducing clinical trial screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease in the U.S. and Canada. The study also highlighted sabirnetug's high selectivity for amyloid beta oligomers over monomers compared to recombinant lecanemab and aducanumab. These findings were presented at the Alzheimer's Association International Conference $(AAIC)$ 2025, held in Toronto and online. The innovative two-step screening process using a plasma pTau217 biomarker assay contributed to significant cost efficiencies and helped achieve strong enrollment rates by reducing unnecessary procedures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.